Chemical Strategy and AI-Enabled Peptide Vaccine Development.

Area of Science:

• Vaccinology
• Immunoinformatics
• Medicinal Chemistry

Background:

• Peptide vaccines offer safety and precision but face challenges with immunogenicity, HLA restriction, and stability.
• Traditional epitope discovery relies on empirical methods, limiting rational design.

Purpose of the Study:

• To review the integration of AI-driven epitope prediction and chemical modification for next-generation peptide vaccines.
• To highlight how these advances address key limitations of current peptide vaccine technology.

Main Methods:

• Utilizing machine learning models trained on binding assays, mass spectrometry data, and T-cell responses for accurate epitope prediction.
• Employing medicinal chemistry strategies like cyclization, lipidation, and noncanonical amino acid incorporation to enhance peptide properties.
• Developing sequence-based, structure-informed, and pan-allelic frameworks for epitope discovery.

Main Results:

• AI enables precise prediction of peptide-MHC binding and T-cell recognition, moving beyond trial-and-error.
• Chemical modifications improve peptide immunogenicity, stability, and targeted delivery.
• Integration of computational and chemical approaches bridges the gap between *in silico* design and clinical efficacy.

Conclusions:

• The synergy between AI and medicinal chemistry is crucial for developing potent, durable, and safe peptide vaccines.
• Tailored peptide vaccines can be designed for diverse HLA backgrounds and therapeutic objectives.
• These integrated strategies promise to overcome current limitations and advance peptide vaccine development.